« Zurück
Startseite /
Anti-Mouse CD223 (LAG-3) Antibody - Purified in vivo GOLD™ Functional Grade

Anti-Mouse CD223 (LAG-3) Antibody - Purified in vivo GOLD™ Functional Grade

ArtNr	LEIN-L306-5.0mg
Hersteller	Leinco Technologies
Menge	5 mg
Quantity options	1 mg 100 mg 25 mg 5 mg 50 mg
Kategorie	In Vivo Antibodies In Vivo Antibodies
Typ	Antibody Monoclonal
Applikationen	WB, IP, FA, other, IV
Clon	C9B7W
Specific against	Mouse (Murine, Mus musculus)
Host	Rat
Purity	> 95% by SDS-PAGE and ≥ 95% monomer by analytical SEC
NCBI	16768
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Category	Purified in vivo Functional Grade>Gold Purified Bulk Antibodies\|Primary Monoclonal Antibodies>Immune Checkpoints\|Purified in vivo Functional Grade\|Primary Monoclonal Antibodies>Surfacetag Mouse CD Markers
Manufacturer - Targets	CD223
Country of Origin	USA
Shipping Temperature	Next Day 2-8°C
Storage Conditions	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Product Description	LAG-3 is a 70-kD, type-I transmembrane glycoprotein within the Ig superfamily with four extracellular Ig-like domains (D1 to D4) and is structurally homologous to CD4. LAG-3 is a cell surface molecule with various biologic effects on T cell function. It has been reported to be involved in Treg suppressive function. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar manner to CTLA-4 and PD-1. Human LAG-3 is approximately 70% homologous with murine LAG3, and it binds MHC class II molecules with higher affinity than CD4. As an immune checkpoint receptor, LAG-3 is the target of various drug development programs seeking to expand treatments for cancer and autoimmune disorders. In its soluble form, LAG-3 is being developed as a cancer drug. As an antagonist, LAG-3 antibody can activate T effector cells via the downregulation of the LAG-3 inhibiting signal into pre-activated LAG-3+ cells. In addition, it can inhibit antigen-specific Treg suppressive activity. As an agonist antibody, it can be used to diminish an autoimmune response and is currently being investigated for the treatment of plaque psoriasis.
Background	LAG-3 is a 70-kD, type-I transmembrane glycoprotein within the Ig superfamily with four extracellular Ig-like domains (D1 to D4) and is structurally homologous to CD4. LAG-3 is a cell surface molecule with various biologic effects on T cell function. It has been reported to be involved in Treg suppressive function. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar manner to CTLA-4 and PD-1. Human LAG-3 is approximately 70% homologous with murine LAG3, and it binds MHC class II molecules with higher affinity than CD4. As an immune checkpoint receptor, LAG-3 is the target of various drug development programs seeking to expand treatments for cancer and autoimmune disorders. In its soluble form, LAG-3 is being developed as a cancer drug. As an antagonist, LAG-3 antibody can activate T effector cells via the downregulation of the LAG-3 inhibiting signal into pre-activated LAG-3+ cells. In addition, it can inhibit antigen-specific Treg suppressive activity. As an agonist antibody, it can be used to diminish an autoimmune response and is currently being investigated for the treatment of plaque psoriasis.
Other Applications Reported In Literature	B Clone C9B7W antibody blocks the function of murine LAG-3 in vivo.
PubMed	CD223
Manufacturer - Research Area	Immunology, Inhibitory Molecules
Manufacturer - Specificity	Clone C9B7W recognizes and specifically binds to an epitope in the D2 domain of CD223.
RRID	AB_2737552
Concentration	≥ 5.0 mg/ml
Formulation	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Antigen Distribution	CD223 (LAG-3) is expressed on T regulatory cells, activated T cells and NK cells.
Endotoxin Level	≤ 1.0 EU/mg
Immunogen	Murine CD223-Ig fusion protein
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

LEIN-L306-5.0mg-safety-datasheet.pdf